General description
A cell-permeable isoxazolocarboxamide compound that enhances the E-cadherin protein level in lung squamous cell carcinoma H520 and colorectal adenocarcinoma SW620 cells (6.3- and 10-fold, respectively; 10 µM for 24 h) in a dose-dependent manner (EC50 = 1.25 and 2.13 µM, respectively), resulting in an effective culture invasiveness reduction (by ~50% in SW620 invasion assays). The observed cellular E-cadherin protein upregulation correlates well with an increase in both cellular E-cadherin gene CHD1 transcription (10.2-fold increase in SW620 by RNA-Seq analysis;10 µM for 24 h) and histone H4 Lys9 acetylation (19- and 57-fold enhancement in H529 and SW620 cells, respectively; 10 µM for 24 h), although evidence indicates no direct inhibition of HDACs 1-11 activity by the compound and other cellular factors involved in histone acetylation regulation are the likely candidates as the direct drug target(s).
Packaging
Packaged under inert gas
Warning
Toxicity: Regulatory Review (Z)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Stoops, S.L., et al. 2011. ACS Chem. Biol.6, 452.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51122603
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 205615-10MG